Clinical Commander

All dossiers
cardio.nstemi.diabetic-silent.v1

NSTEMI — diabetic silent / atypical (autonomic neuropathy; anginal-equivalent presentation)

cardiologyacuteadultacuteinpatienttransitionoutpatient
Start encounter →Print handoutPRODUCTION

Phase E presentation-typicality variant of cardio.nstemi.core.v1 — narrowed to silent / atypical NSTEMI in diabetes mellitus driven by cardiac autonomic neuropathy (CAN) per Pop-Busui Diabetes Care 2017 PMID 28522672 framework + Canto JAMA 2012 PMID 22340557 atypical MI presentation evidence. Three pathophysiologic anchors: (1) CAN blunts pain perception (small-fiber sensory denervation); (2) microvascular dysfunction + accelerated diffuse multi-vessel CAD; (3) anginal equivalents (dyspnea, fatigue, nausea, syncope, unexplained hypoglycemia, new HF). Lower threshold for serial 0/1-h hsTn + early ECG + bedside echo for any diabetic with these presentations, particularly with microalbuminuria, retinopathy, peripheral neuropathy, or known CAN markers. Diabetes-specific regimen layer: (1) glycemic control 140-180 in critical illness (insulin infusion if persistent >180 per DIGAMI PMID 9099043 + ADA 2026); (2) HOLD metformin peri-cath × 48 h (FDA label — contrast/lactic acidosis); (3) HOLD SGLT2i if DKA risk (NPO, sepsis, peri-procedural); (4) initiate or continue SGLT2i + GLP-1 RA post-stabilization for cardio-renal benefit per EMPA-REG PMID 26378978 + DECLARE PMID 30415602 + LEADER PMID 27295427 + DAPA-MI PMID 38320150; (5) cardioselective beta-blocker preferred to minimize hypoglycemia masking; (6) ACEi/ARB for diabetic nephropathy + CV benefit per HOPE PMID 10639539; (7) ticagrelor preferred per PLATO DM subgroup. Long-term targets per ADA 2026 individualization: A1c 7-7.5%, BP <130/80 (KDIGO 2026 + ACC/AHA 2025), LDL <70 (or <55 very-high-risk per ESC 2023), SGLT2i + GLP-1 RA lifelong cardio-renal benefit; annual eye + foot + UACR screening; cardiac rehab phase II with diabetes-specific glycemic monitoring. Sister engines: cardio.nstemi.octogenarian-conservative.v1 (atypical-presentation by AGE; both engines apply when octogenarian + diabetic with HBR resolving DAPT preference); cardio.nstemi.intermediate-risk.v1 (atypical-presentation by RISK STRATUM; both engines apply for diabetic-silent typically intermediate risk); cardio.acute-hf.diabetic-cardiomyopathy.v1 (chronic HF substrate; cross-link explicit). Status INTEGRATED authored 2026-05-15 by shard-06-cardio-acute as part of the Phase E NSTEMI-by-presentation wave 24.

Entry points (6)

  • symptom
    Unexplained dyspnea or fatigue in T2DM patient with microalbuminuria, retinopathy, or peripheral neuropathy — anginal-equivalent silent NSTEMI suspect; low threshold for serial hsTn + ECG
    unexplained_dyspnea_in_diabetic_with_microvascular_disease
  • symptom
    Nausea, diaphoresis, or syncope in diabetic patient — anginal-equivalent presentation per Canto JAMA 2012 PMID 22340557; women with diabetes even more likely atypical
    nausea_diaphoresis_syncope_in_diabetic
  • lab_abnormality
    Unexplained hypoglycemia in diabetic patient (counter-regulatory failure during ischemia) — silent MI consideration
    unexplained_hypoglycemia_in_diabetic_with_concerning_features
  • history
    Diabetic patient with resting tachycardia >100, orthostatic SBP drop ≥20, or known CAN markers presenting with anginal equivalent — high pre-test probability silent ischemia
    diabetic_with_resting_tachycardia_or_orthostasis_with_anginal_equivalent
  • lab_abnormality
    Rising hsTn in diabetic patient admitted for unrelated reason (CHF, infection, dyspnea workup) — silent NSTEMI may be incidentally detected
    rising_hstn_in_diabetic_admitted_for_other_reason
  • imaging
    New regional wall-motion abnormality on bedside echo for diabetic patient with dyspnea or unexplained CHF — silent NSTEMI suspect
    new_rwma_on_echo_in_diabetic_without_chest_pain

Required inputs (13)

  • agerequired
    demographic • used at CONTEXT
    Diabetic patients with longer disease duration and higher A1c have higher CAN prevalence; age + diabetes duration interact
  • diabetes_diagnosis_and_durationrequired
    history • used at FRAME
    T2DM > T1DM for silent ischemia; duration ≥10 y and A1c ≥7 raise CAN probability per DCCT/EDIC + Pop-Busui PMID 28522672
  • microvascular_complication_statusrequired
    history • used at CONTEXT
    Microalbuminuria, retinopathy, peripheral neuropathy markers correlate with CAN; presence raises silent ischemia probability and lowers cath threshold
  • autonomic_neuropathy_markers
    history • used at CONTEXT
    Resting tachycardia >100, orthostatic SBP drop ≥20, abnormal heart rate variability, gastroparesis, sexual dysfunction — clinical CAN markers per Pop-Busui PMID 28522672
  • hs_troponin_serialrequired
    lab • used at INITIAL_WORKUP
    ESC 2023 0/1-h hsTn algorithm — lower threshold for serial trop in any diabetic with anginal-equivalent presentation; chronic elevation common in diabetic nephropathy + HFpEF — dynamic delta required
  • ecg_serialrequired
    imaging • used at INITIAL_WORKUP
    Confirm absence of STE (this is NSTEMI variant); detect ST depression, T inversion, dynamic changes; baseline ECG abnormalities common in diabetes (LVH, pre-existing T-wave changes) confound
  • a1c_baselinerequired
    lab • used at CONTEXT
    A1c at admission documents glycemic control history + drives long-term diabetes management; elevated A1c worsens ACS outcomes per DIGAMI
  • glucose_baseline_and_serialrequired
    lab • used at INITIAL_WORKUP
    Hyperglycemia >180 worsens ACS outcomes per DIGAMI/HI-5; hypoglycemia drives counter-regulatory failure during ischemia; target 140-180 in critically-ill ACS per ADA 2026
  • creatinine_egfrrequired
    lab • used at INITIAL_WORKUP
    Diabetic nephropathy common; CKD-EPI 2021 race-free eGFR gates contrast, DOAC, gabapentinoid dosing; KDIGO 2026 pre-hydration if cath proceeds
  • urine_albumin_creatinine_ratio
    lab • used at CONTEXT
    Microalbuminuria marker for diabetic nephropathy + microvascular disease + CAN association; raises silent ischemia probability
  • echo_with_rwma_assessmentrequired
    imaging • used at BRANCHING_WORKUP
    Bedside echo for new RWMA — particularly important in diabetics where pain perception is blunted and clinical exam may underestimate ischemic burden
  • current_diabetes_medsrequired
    medication • used at CONTEXT
    Metformin HOLD peri-cath (contrast nephropathy → lactic acidosis); SGLT2i HOLD if DKA risk (NPO, sepsis); insulin titration plan; GLP-1 RA continuation per ADA 2026
  • sbprequired
    vital • used at RED_FLAGS
    Hypotension as both red flag (silent shock) and trigger consideration; orthostatic SBP drop ≥20 a CAN marker

12-phase flow (12)

  1. 1FRAME
    Confirm NSTEMI in diabetic patient with atypical / anginal-equivalent presentation per Canto JAMA 2012 PMID 22340557 + Pop-Busui PMID 28522672 CAN framework. Anchor to three drivers: (1) cardiac autonomic neuropathy blunting pain perception, (2) microvascular dysfunction + accelerated diffuse CAD, (3) anginal equivalents (dyspnea, fatigue, nausea, syncope, unexplained hypoglycemia)
    inputs: diabetes_diagnosis_and_duration, hs_troponin_serial, ecg_serial
    advance: Diabetic silent NSTEMI confirmed + CAN context framed
  2. 2ENTRY
    Triage with serial 0/1-h hsTn + early ECG (presentation may be late); document microvascular + CAN markers; bedside echo within 1 h for any diabetic with unexplained dyspnea or hypotension
    inputs: age, a1c_baseline
    advance: Pathway started + diabetes context catalogued
  3. 3CONTEXT
    Diabetes history (type, duration, A1c trajectory, current regimen, last endocrinology visit), microvascular complications (retinopathy, microalbuminuria, neuropathy), CAN markers (resting tachycardia, orthostasis, gastroparesis), comorbidities (CKD, HFpEF, PAD, CVA), allergies, prior cath if any
    inputs: microvascular_complication_status, autonomic_neuropathy_markers, urine_albumin_creatinine_ratio, creatinine_egfr, current_diabetes_meds, sbp
    advance: Diabetes + CV context complete
  4. 4RED_FLAGS
    Hemodynamic instability (silent shock — diabetics may not feel pain even in CS); sustained VT/VF; acute heart failure with new RWMA; severe hypoglycemia (<54) with confusion + concerning features; hyperosmolar hyperglycemic state (HHS) overlap
    inputs: sbp, glucose_baseline_and_serial
    actions: cardiogenic_shock, acs_pathway
    advance: Red flags screened + escalation triggers documented
  5. 5INITIAL_WORKUP
    Serial 0/1-h hsTn (interpret kinetics: chronic elevation common in diabetic nephropathy/HFpEF, dynamic delta required), serial ECG, BMP (eGFR), CBC, A1c, lipid panel, BNP/NT-proBNP (frequently elevated in diabetic HFpEF — supports HF differential), bedside echo for new RWMA, UA + UACR for microalbuminuria
    inputs: hs_troponin_serial, ecg_serial, creatinine_egfr, glucose_baseline_and_serial, echo_with_rwma_assessment
    actions: acs_pathway, panel.cardiac, panel.renal, panel.cbc
    advance: Diagnostic workup complete + NSTEMI confirmed
  6. 6BRANCHING_WORKUP
    Bedside echo if not done; consider CMR or stress imaging if conservative path elected; diabetes-specific bundle: HHS/DKA workup if glucose >300 + osmolality elevated; HF workup with BNP if dyspnea predominant; PE workup if dyspnea + tachycardia (diabetes is independent VTE risk)
    actions: chest_pain
    advance: Branching diagnostics complete
  7. 7DIFFERENTIAL
    Type-1 NSTEMI (plaque rupture in accelerated CAD) — most likely in this engine; Type-2 NSTEMI (demand from sepsis/anemia/HFpEF decompensation in diabetic substrate); diabetic ketoacidosis with secondary trop bump; HFpEF decompensation with chronic trop; PE with strain pattern + trop; aortic dissection (diabetic vasculopathy)
    advance: Driver classified
  8. 8RISK_STRATIFICATION
    HEART score (DM = 1 risk factor); TIMI-NSTEMI (DM = 1 point); GRACE 2.0 captures DM + creatinine + age — diabetic patients typically intermediate-to-high risk; SOFA if multi-organ dysfunction; CKD-EPI for contrast/dosing; CHA2DS2-VASc if AF detected; MAP for shock screening
    inputs: age, sbp, creatinine_egfr, hs_troponin_serial
    actions: calc.heart, calc.ckd_epi_2021, calc.cha2ds2vasc, calc.sofa, calc.map
    advance: Risk stratification documented; cath strategy aligned
  9. 9TREATMENT
    Standard NSTE-ACS bundle (ASA + P2Y12 + parenteral AC + statin) with diabetes-specific layer: (1) glycemic control 140-180 in critical illness (insulin infusion if persistent >180 per ADA 2026 + DIGAMI); (2) HOLD metformin peri-cath × 48 h (FDA label — contrast/lactic acidosis); (3) HOLD SGLT2i if DKA risk (NPO, sepsis, peri-proc); (4) initiate or continue SGLT2i + GLP-1 RA post-stabilization for cardio-renal benefit per EMPA-REG/DECLARE/LEADER/REWIND/DAPA-MI; (5) high-intensity statin lifelong; (6) ACEi/ARB for diabetic nephropathy + CV benefit per HOPE PMID 10639539
    inputs: creatinine_egfr, glucose_baseline_and_serial
    actions: protocol.stemi
    advance: Standard ACS bundle + diabetes-specific regimen documented
  10. 10DISPOSITION
    Telemetry on cardiology service; endocrinology consult for glycemic management if A1c >9 or insulin pump / complex regimen; nutrition consult for diabetes-specific diet; cardiac rehab phase I bedside
    advance: Disposition + endo + nutrition consults documented
  11. 11MONITORING
    Telemetry; serial trop to confirm trend; daily ECG; glucose q4h with insulin sliding scale or basal-bolus per ADA 2026 inpatient targets 140-180; BMP daily on AC + ACEi/ARB; renal trajectory (CIN-AKI surveillance); CAN markers reassessed; falls precautions if orthostatic
    inputs: creatinine_egfr, glucose_baseline_and_serial
    actions: panel.cardiac, panel.renal
    advance: Monitoring orders + glycemic plan documented
  12. 12FOLLOWUP
    Cardiology + endocrinology joint follow-up at 1, 4, 12 wks; LVEF re-echo at 40-90 d for ICD eligibility (MADIT-II EF ≤30); cardiac rehab Class I per ACC/AHA 2025 with diabetes-specific glycemic monitoring; intensified secondary prevention (high-intensity statin lifelong, BP <130/80, A1c 7-7.5% individualized per ADA 2026, SGLT2i/GLP-1 RA cardio-renal); annual eye + foot + microalbuminuria screening
    advance: Long-term joint follow-up + cardiac rehab booked